Skip to content

Trial Summary

 This is a multicenter, randomized, open-label, controlled Phase 3 trial of XL092 + atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed after or are intolerant to standard-of-care (SOC) therapy.



ACTRN/NCT /ethics:


Scientific title:

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeColorectal Cancer
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2023-09-07
Anticipated End Date2026-02-01

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Phone08 8222 6140
Principal InvestigatorTim Price
Recruitment StatusRecruiting